Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?


Abali H., Yavuz S., Calikusu Z., Seyrek E.

ANNALS OF ONCOLOGY, cilt.26, ss.245, 2015 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 26 Konu: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1093/annonc/mdu473
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Sayfa Sayısı: ss.245

Özet

This letter criticize the design of ACTS-CC trial; patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.